Related references
Note: Only part of the references are listed.GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence
Holger J. Schunemann et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis
Do Kyung Kim et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis
Jianhong Zhu et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer
Roberto Iacovelli et al.
CLINICAL GENITOURINARY CANCER (2018)
A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer
Daniel E. Spratt et al.
EUROPEAN UROLOGY (2018)
Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
Maxine Sun et al.
JOURNAL OF UROLOGY (2018)
Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer
Philipp Gild et al.
JOURNAL OF UROLOGY (2018)
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis
Giandomenico Roviello et al.
MEDICAL ONCOLOGY (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study
Huah Shin Ng et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis
Zhenlang Guo et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis
Kevin T. Nead et al.
UROLOGY (2018)
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
Larysa H. M. Rydzewska et al.
EUROPEAN JOURNAL OF CANCER (2017)
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
Huei-Ting Tsai et al.
JOURNAL OF UROLOGY (2017)
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
K. T. Nead et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis
Kevin T. Nead et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
Beverley J. Shea et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
Beverley J. Shea et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
J. N. Graff et al.
ANNALS OF ONCOLOGY (2016)
Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
Brian D. Gonzalez et al.
SUPPORTIVE CARE IN CANCER (2016)
Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review
Fanzheng Meng et al.
BMC CANCER (2016)
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials
Giandomenico Roviello et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies
Lucie-Marie Scailteux et al.
MEDICINE (2016)
A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
Alessandro Sciarra et al.
MEDICINE (2016)
A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients
C. Jin et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation
Christopher J. D. Wallis et al.
UROLOGY (2016)
Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis
Huimin Wang et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy Effects of Androgen-Deprivation Therapy
Maxine Sun et al.
JAMA ONCOLOGY (2016)
Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review
Frank Kunath et al.
BJU INTERNATIONAL (2015)
Long-term impact of androgen-deprivation therapy on physical function and quality of life
Shabbir M. H. Alibhai et al.
CANCER (2015)
Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
Cecilia Bosco et al.
EUROPEAN UROLOGY (2015)
The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy
Juan Morote et al.
JOURNAL OF UROLOGY (2015)
Gynecomastia in Patients with Prostate Cancer: A Systematic Review
Anders Fagerlund et al.
PLOS ONE (2015)
Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer A Systematic Review and Meta-analysis
Sindy Magnan et al.
JAMA ONCOLOGY (2015)
Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis
Cecilia Bosco et al.
PLOS ONE (2015)
Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
Morgan Lee et al.
PSYCHO-ONCOLOGY (2015)
Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis
Arie Carneiro et al.
WORLD JOURNAL OF UROLOGY (2015)
Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies
Jinsheng Zhao et al.
PLOS ONE (2014)
Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study
A. K. Morgans et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2014)
Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis
Heather L. McGinty et al.
SUPPORTIVE CARE IN CANCER (2014)
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications
Yu-Hsuan Shao et al.
BJU INTERNATIONAL (2013)
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
L. Bourke et al.
BRITISH JOURNAL OF CANCER (2013)
Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review
Alison Pearce et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2013)
Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States
Jennifer L. Beebe-Dimmer et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: An analysis of the 4-versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01)
Patricia E. Daly et al.
RADIOTHERAPY AND ONCOLOGY (2012)
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer A Meta-analysis of Randomized Trials
Paul L. Nguyen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Christopher U. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
An update on androgen deprivation therapy for prostate cancer
Nima Sharifi et al.
ENDOCRINE-RELATED CANCER (2010)
Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men
Shabbir M. H. Alibhai et al.
JOURNAL OF UROLOGY (2010)
Falls in men on androgen deprivation therapy for prostate cancer
Shabbir Hussain et al.
JOURNAL OF GERIATRIC ONCOLOGY (2010)
The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis
Farhana Haseen et al.
JOURNAL OF CANCER SURVIVORSHIP (2010)
Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values
Vivek K. Wadhwa et al.
BJU INTERNATIONAL (2009)
Review of Major Adverse Effects of Androgen-deprivation Therapy in Men With Prostate Cancer
Lockwood G. Taylor et al.
CANCER (2009)
Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: A systematic review and meta-analysis of randomised trials
M. D. Shelley et al.
CANCER TREATMENT REVIEWS (2009)
Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation
D. A. Galvao et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer - Differences from the classic metabolic syndrome
Matthew R. Smith et al.
CANCER (2008)
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer - A randomized trial
Susan L. Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
S. Kumar et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
Chronic medical illness, depression, and use of acute medical services among medicare beneficiaries
S Himelhoch et al.
MEDICAL CARE (2004)
Share Paper
